Authorized purpose: CARA assists adult structural-heart and conduction-system procedure planning by segmenting preprocedural CT, visualizing cardiac chambers and conduction landmarks, and overlaying a reviewed three-dimensional roadmap on live fluoroscopy.
Clinical role
Preprocedural CT segmentation and cardiac-conduction roadmap overlay during fluoroscopy-guided procedures.
Images and patients
Fluoroscopy/Angiography · Heart/Cardiovascular
Key limitation
Keep in mind: The clinician must review the segmentation and landmarks. The software is an adjunct to, not a replacement for, procedural judgment, imaging review, or standard localization methods.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: CARA assists adult structural-heart and conduction-system procedure planning by segmenting preprocedural CT, visualizing cardiac chambers and conduction landmarks, and overlaying a reviewed three-dimensional roadmap on live fluoroscopy.
Which images or clinical context are in scope?Modality: Fluoroscopy/Angiography Anatomy or clinical context: Heart/Cardiovascular Input: Preprocedural cardiac CT in DICOM format and live fluoroscopy for overlay guidance.
Who uses it?Intended users: Qualified physicians and trained procedural staff performing adult cardiac procedure planning and guidance.
What does the software produce?Output: Reviewed three-dimensional cardiac anatomy and conduction-landmark roadmap with fluoroscopic overlay.
What is its most important limitation?Key limitation: The clinician must review the segmentation and landmarks. The software is an adjunct to, not a replacement for, procedural judgment, imaging review, or standard localization methods.
Clinical takeaway. Clinical role: CARA assists adult structural-heart and conduction-system procedure planning by segmenting preprocedural CT, visualizing cardiac chambers and conduction landmarks, and overlaying a reviewed three-dimensional roadmap on live fluoroscopy.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports non-clinical, AI/ML validation, and retrospective clinical testing: phantom CT-to-fluoroscopy registration (mean registration error of ≤ 2.0 mm); validation against annotations by trained technologists adjudicated by an interventional cardiologist (CT cardiac-chamber segmentation on 50 retrospective CT scans: all evaluated structures met criteria; fluoroscopic aortic segmentation on 480 images: Mean DSC = 0.962); and a retrospective clinical study on 403 patients evaluating the device's utility in visualizing the conduction system. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
CARA assists adult structural-heart and conduction-system procedure planning by segmenting preprocedural CT, visualizing cardiac chambers and conduction landmarks, and overlaying a reviewed three-dimensional roadmap on live fluoroscopy.
Exact FDA submission
Checked 2026-09-04
Added in P2 round17 from the exact FDA decision material; later product-family claims remain separate.
The clinician must review the segmentation and landmarks. The software is an adjunct to, not a replacement for, procedural judgment, imaging review, or standard localization methods.
The exact FDA document reports non-clinical, AI/ML validation, and retrospective clinical testing: phantom CT-to-fluoroscopy registration (mean registration error of ≤ 2.0 mm); validation against annotations by trained technologists adjudicated by an interventional cardiologist (CT cardiac-chamber segmentation on 50 retrospective CT scans: all evaluated structures met criteria; fluoroscopic aortic segmentation on 480 images: Mean DSC = 0.962); and a retrospective clinical study on 403 patients evaluating the device's utility in visualizing the conduction system. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Comprehensive non-clinical, AI/ML validation, and retrospective clinical performance testing were conducted to demonstrate substantial equivalence" … "CT-to-fluoroscopy registration testing validated geometric alignment between the CT-derived model and live fluoroscopy using landmark-based comparison against ground truth in phantom. The system achieved a mean registration error of ≤ 2.0 mm". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports non-clinical, AI/ML validation, and retrospective clinical testing: phantom CT-to-fluoroscopy registration (mean registration error of ≤ 2.0 mm); validation against annotations by trained technologists adjudicated by an interventional cardiologist (CT cardiac-chamber segmentation on 50 retrospective CT scans: all evaluated structures met criteria; fluoroscopic aortic segmentation on 480 images: Mean DSC = 0.962); and a retrospective clinical study on 403 patients evaluating the device's utility in visualizing the conduction system. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Comprehensive non-clinical, AI/ML validation, and retrospective clinical performance testing were conducted to demonstrate substantial equivalence" … "CT-to-fluoroscopy registration testing validated geometric alignment between the CT-derived model and live fluoroscopy using landmark-based comparison against ground truth in phantom. The system achieved a mean registration error of ≤ 2.0 mm". Read from the exact FDA decision document on 2026-11-14.
Sensitivity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or dose-delivery function. Use the task-specific endpoints and tested population reported below.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-03
Specificity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or dose-delivery function. Use the task-specific endpoints and tested population reported below.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K252500 FDA performance package for CARA System
DesignManufacturer nonclinical verification and validation of segmentation, anatomical landmark modeling, registration, and live fluoroscopy overlay
PopulationAdult preprocedural cardiac CT and representative fluoroscopy-guided workflow data described in K252500
Scopeexact submission
Tested versionCARA System cleared in K252500
IndependenceSponsor or vendor study
K252500
Manufacturer evidence submitted for substantial equivalence; local clinical, technical, and workflow acceptance remains necessary.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the device within the applicable imaging or surgical service line and verify payer, site-of-service, and coding assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Preprocedural cardiac CT in DICOM format and live fluoroscopy for overlay guidance.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Planning workstation and procedure-room integration; current CARA Metis and Atlas materials describe the product family, not every K252500 configuration.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Unresolved route: Reviewed three-dimensional cardiac anatomy and conduction-landmark roadmap with fluoroscopic overlay.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Planning workstation and procedure-room integration; current CARA Metis and Atlas materials describe the product family, not every K252500 configuration.
Only qualified physicians and trained procedural staff performing adult cardiac procedure planning and guidance. should operate or interpret the system. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: The clinician must review the segmentation and landmarks. The software is an adjunct to, not a replacement for, procedural judgment, imaging review, or standard localization methods.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The clinician must review the segmentation and landmarks. The software is an adjunct to, not a replacement for, procedural judgment, imaging review, or standard localization methods.
exact submission · checked 2026-09-03
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-03
Vendor productivity claims are scenario inputs, not guaranteed local savings.
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: The clinician must review the segmentation and landmarks. The software is an adjunct to, not a replacement for, procedural judgment, imaging review, or standard localization methods.
exact submission · checked 2026-09-03
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
26Fields reviewed
11Source classes checked
20Screened PubMed leads
10Screened trial leads
0Unreviewed FDA recall leads
Twenty PubMed records and ten trial records were screened. Most are CARA acronym collisions; NCT05657912 and NCT05465655 concern CARA CDRS/CDRM rather than the K252500 CARA System. No evidence was promoted, and all 30 candidates remain quarantined. The current discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, vendor product page, reimbursement policy, fda device recall, fda decision material, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-03 - Exact FDA submission
Public materials reviewed for this batch do not establish the complete security posture for the exact release. Request data-flow, identity, audit, encryption, retention, support-access, vulnerability-management, backup, and incident-response evidence.
Authorized purpose: QFR (3.0) uses paired coronary X-ray angiographic DICOM acquisitions to calculate three-dimensional vessel and lesion measurements and pressure-drop quantification for interventional cardiologist or researcher review in patients with coronary artery disease.
Authorized purpose: TAVIPILOT detects, tracks, and marks the non-coronary cusp and prosthetic valve on live fluoroscopy during specified adult femoral TAVR or TAVI procedures under physician control.
Authorized purpose: Trinias is an interventional fluoroscopic X-ray system for diagnostic and interventional angiography, including cardiac, neurovascular, abdominal, peripheral, rotational, multipurpose, and whole-body radiographic or fluoroscopic procedures.
Modality
Fluoroscopy/Angiography
Anatomy
Heart, neurovascular, abdominal, peripheral vessels, and whole body
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.